1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 2016. View Article : Google Scholar
|
4
|
Wilson CB: Glioblastoma: The past, the
present, and the future. Clin Neurosurg. 38:32–48. 1992.PubMed/NCBI
|
5
|
Glas M, Rath BH, Simon M, Reinartz R,
Schramme A, Trageser D, Eisenreich R, Leinhaas A, Keller M,
Schildhaus HU, et al: Residual tumor cells are unique cellular
targets in glioblastoma. Ann Neurol. 68:264–269. 2010.PubMed/NCBI
|
6
|
Grzmil M, Seebacher J, Hess D, Behe M,
Schibli R, Moncayo G, Frank S and Hemmings BA: Inhibition of MNK
pathways enhances cancer cell response to chemotherapy with
temozolomide and targeted radionuclide therapy. Cell Signal.
28:1412–1421. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lorenzetti M, Motta F, Campanella R, Bauer
D, Assi A, Arienta C, Gaini SM and Caroli M: Adjuvant temozolomide
chemotherapy for treatment of papillary tumor of the pineal region.
World Neurosurg. 76:160–163. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pace A, Vidiri A, Galiè E, Carosi M,
Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B and
Carapella CM: Temozolomide chemotherapy for progressive low-grade
glioma: Clinical benefits and radiological response. Ann Oncol.
14:1722–1726. 2003. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sarkaria JN, Kitange GJ, James CD, Plummer
R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to
alkylating agents in malignant glioma. Clin Cancer Res.
14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Segal MS, Goldstein MM and Attinger EO:
The use of noscapine (narcotine) as an antitussive agent. Dis
Chest. 32:305–309. 1957. View Article : Google Scholar : PubMed/NCBI
|
11
|
St-Coeur PD, Poitras JJ, Cuperlovic-Culf
M, Touaibia M and Morin P Jr: Investigating a signature of
temozolomide resistance in GBM cell lines using metabolomics. J
Neurooncol. 125:91–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Akasaka-Manya K, Manya H, Kobayashi K,
Toda T and Endo T: Structure-function analysis of human protein
O-linked mannose beta1,2-N-acetylglucosaminyltransferase 1,
POMGnT1. Biochem Biophys Res Commun. 320:39–44. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Lan J, Guo P, Chen M, Wu B, Mao Q and Qiu
Y: O-linked mannose β-1,2-N-acetylglucosaminyltransferase 1
correlated with the malignancy in glioma. J Craniofac Surg.
24:1441–1446. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lan J, Guo P, Lin Y, Mao Q, Guo L, Ge J,
Li X, Jiang J, Lin X and Qiu Y: Role of glycosyltransferase PomGnT1
in glioblastoma progression. Neuro-oncol. 17:211–222. 2015.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Abbott KL, Troupe K, Lee I and Pierce M:
Integrin-dependent neuroblastoma cell adhesion and migration on
laminin is regulated by expression levels of two enzymes in the
O-mannosyl-linked glycosylation pathway, PomGnT1 and GnT-Vb. Exp
Cell Res. 312:2837–2850. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Abbott KL, Troupe K, Matthews RT and
Pierce M: GnT-Vb expression increases O-mannosyl-linked HNK-1
epitope leading to changes in neuronal cell adhesion and migration.
Glycobiology. 16:1111. 2006.
|
17
|
Miller MR, Ma D, Schappet J, Breheny P,
Mott SL, Bannick N, Askeland E, Brown J and Henry MD:
Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD
associate with increased mortality in clear cell renal cell
carcinoma. Mol Cancer. 14:1412015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
19
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
20
|
Makker A and Goel MM: Tumor progression,
metastasis and modulators of EMT in endometrioid endometrial
carcinoma: An update. Endocr Relat Cancer. 23:R85–R111. 2015.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Shen Y, Zhou J, Li Y, Ye F, Wan X, Lu W,
Xie X and Cheng X: miR-375 mediated acquired chemo-resistance in
cervical cancer by facilitating EMT. PLoS One. 9:e1092992014.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Toge M, Yokoyama S, Kato S, Sakurai H,
Senda K, Doki Y, Hayakawa Y, Yoshimura N and Saiki I: Critical
contribution of MCL-1 in EMT-associated chemo-resistance in A549
non-small cell lung cancer. Int J Oncol. 46:1844–1848. 2015.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Zou C, Lu Y, Mizokami A, Keller ET, Pienta
KJ and Zhang J: CCL2 and interleukin-6 regulate EMT-mediated
chemo-resistance in prostate cancer. Cancer Res. 72 Suppl:Abst
841–841. 2012. View Article : Google Scholar
|
24
|
Liang SQ, Marti TM, Dorn P, Froment L,
Hall SR, Berezowska S, Kocher G, Schmid RA and Peng RW: Blocking
the epithelial-to-mesenchymal transition pathway abrogates
resistance to anti-folate chemotherapy in lung cancer. Cell Death
Dis. 6:e18242015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Liang S, Marti TM, Dorn P, Froment L, Hall
S, Berezowska S, Kocher G, Schmid RA and Peng R: 18P
Epithelial-to-mesenchymal transition (EMT) is required for
resistance to anti-folate chemotherapy in lung cancer. J Thorac
Oncol. 11:(Suppl) S632016. View Article : Google Scholar
|
26
|
Stupp R, Hegi ME, Van den Bent MJ, Mason
WP, Weller M, Mirimanoff RO and Cairncross JG; European
Organisation for Research and Treatment of Cancer Brain Tumor and
Radiotherapy Groups, ; National Cancer Institute of Canada Clinical
Trials Group, : Changing paradigms: an update on the
multidisciplinary management of malignant glioma. Oncologist.
11:165–180. 2006. View Article : Google Scholar : PubMed/NCBI
|
27
|
Dehdashti AR, Hegi ME, Regli L, Pica A and
Stupp R: New trends in the medical management of glioblastoma
multiforme: The role of temozolomide chemotherapy. Neurosurg Focus.
20:E62006.PubMed/NCBI
|
28
|
Lu C and Shervington A: Chemoresistance in
gliomas. Mol Cell Biochem. 312:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kroemer G, Galluzzi L, Vandenabeele P,
Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS,
Golstein P, Green DR, et al: Nomenclature Committee on Cell Death
2009: Classification of cell death: Recommendations of the
Nomenclature Committee on Cell Death 2009. Cell Death Differ.
16:3–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Vega EA, Graner MW and Sampson JH:
Combating immunosuppression in glioma. Future Oncol. 4:433–442.
2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Zhu Z, Du S, Ding F, Guo S, Ying G and Yan
Z: Ursolic acid attenuates temozolomide resistance in glioblastoma
cells by downregulating O6-methylguanine-DNA
methyltransferase (MGMT) expression. Am J Transl Res. 8:3299–3308.
2016.PubMed/NCBI
|
32
|
Bobola MS, Kolstoe DD, Blank A,
Chamberlain MC and Silber JR: Repair of 3-methyladenine and abasic
sites by base excision repair mediates glioblastoma resistance to
temozolomide. Front Oncol. 2:1762012. View Article : Google Scholar : PubMed/NCBI
|
33
|
McConkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
34
|
She X, Yu Z, Cui Y, Lei Q, Wang Z, Xu G,
Luo Z, Li G and Wu M: miR-181 subunits enhance the chemosensitivity
of temozolomide by Rap1B-mediated cytoskeleton remodeling in
glioblastoma cells. Med Oncol. 31:8922014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Vester-Christensen MB, Halim A, Joshi HJ,
Steentoft C, Bennett EP, Levery SB, Vakhrushev SY and Clausen H:
Mining the O-mannose glycoproteome reveals cadherins as major
O-mannosylated glycoproteins. Proc Natl Acad Sci USA. 110:pp.
21018–21023. 2013; View Article : Google Scholar : PubMed/NCBI
|